Intarcia Therapeutics Competitors and Similar CompaniesClear all
Intarcia Therapeutics's competitors and similar companies include Marinus Pharmaceuticals, Zogenix, Sarepta Therapeutics and Livzon Pharmaceutical Group.
 Intarcia Therapeutics Intarcia Therapeutics is a biopharmaceutical company developing therapies for chronic diseases. |  Zogenix Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. |  Livzon Pharmaceutical Group Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products. | ||
Founding Date | Founding Date 1997 | Founding Date 2003 | Founding Date 2006 | Founding Date 1980 | Founding Date 1985 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Boston, US HQ Durham, US Hayward, US | Locations Radnor, US HQ | Locations Emeryville, US HQ Maidenhead, GB | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations Zhuhai, CN HQ Chengdu, CN Qingyuan, CN Shanghai, CN Shaoguan, CN Shenzhen, CN Zhuhai, CN |
Employees | Employees 822% decrease | Employees 402% decrease | Employees 743% increase | Employees 1,31413% increase | Employees 9,067 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 16 m | Valuation ($) N/A | Valuation ($) 12.4 b | Valuation ($) 4.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $31m (FY, 2023) | Revenue (est.) $81.7m (FY, 2021) | Revenue (est.) $2.2b (FY, 2025) | Revenue (est.) ¥11.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $4.8m (FY, 2021) | Cost of goods $25.5m (FY, 2025) | Cost of goods ¥4.1b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) | Gross profit ¥7.8b (FY, 2025) |
Net income | Net income N/A | Net income ($141.4m) (FY, 2023) | Net income ($227.4m) (FY, 2021) | Net income ($713.4m) (FY, 2025) | Net income ¥2.4b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 81.8m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Marinus Pharmaceuticals
HQ
Radnor, US
Employees
40↓ 2% decrease
Marinus Pharmaceuticals is a clinical stage biopharmaceutical company.
View companyZogenix
HQ
Emeryville, US
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View companyLivzon Pharmaceutical Group
HQ
Zhuhai, CN
Employees
9,067
Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products.
View company